Ballicules.com

Ibutilide

CORVERT

Ibutilide ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Ibutilide ballicule

What it isClass III hERG potassium-channel blocker; acute conversion of atrial flutter and fibrillation.

Why this oneIt converts atrial flutter more reliably than atrial fibrillation and acts rapidly by infusion.

What limits itPotentially fatal torsades requires continuous ECG observation after dosing with magnesium and resuscitation capability available.

Ibutilide molecular structure (skeletal formula)
Molecular structure: Ibutilide

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Atrial fibrillation/flutter (conversion to sinus rhythm)≥60 kg1 mg (one vial) IV over 10 min1 mg IV over 10 min
Atrial fibrillation/flutter<60 kg0.01 mg/kg (0.1 mL/kg) IV over 10 min0.01 mg/kg IV over 10 min

Renal Undefined

Hepatic Undefined

May repeat same dose once, 10 min after completion of first infusion, if arrhythmia persists

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy Teratogenic and embryocidal in rats; give only if benefit outweighs fetal risk

Lactation Undefined

Cost

Ibutilide (CORVERT)
Strength#/mogeneric $/unitCostPlus
0.1 mg/mLinjper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Ibutilide is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

⚠ BOXED WARNING

Classes and tags

Clinical profile

Therapeutic safety burden4 / 4
Overdose danger3 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades4 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Defining liabilityAcute torsades and other life-threatening ventricular arrhythmias

Open Ibutilide in the interactive console ↗